Eliquis enters the DVT business

Share this article:
Eliquis enters the DVT business
Eliquis enters the DVT business

Slow-to-build blood drug Eliquis got a potential market boost Friday when the Food and Drug Administration approved the medication's use as a deep vein thrombosis preventative measure among knee- and/or hip-replacement patients.

The blood clot, known as DVT, can also cause a pulmonary embolism, which means that a blood clot, usually in the lower leg, has broken off and migrated to the brain. Partners Bristol-Myers Squibb and Pfizer say the potential patient pools include those receiving the 719,000 knee replacements and 332,000 hip replacements performed in the US every year.

The added advantage is that it adds to the promotional scripts sales forces can employ when talking about the blood thinner, whose stroke-reduction peers include warfarin, Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa.

"The biggest hurdle in primary care has really been so far the entrenchment of warfarin,” Giovanni Caforio, BMS president of US pharmaceuticals, told investors in July. Eliquis sales have not been overwhelming and Caforio said in July that BMS's marketing plan included showering cardiologists with full data sets and providing educational forums that would turn doctors into “believers and trialists.”

The FDA approved the drug in late 2012, and last year's sales added $146 million to the BMS balance sheet. Since then, informatics company AdverseEvents reported that Eliquis patients had a relatively lower number of serious adverse reactions compared to Xarelto and Pradaxa.

This report did not sit well with Xarelto's maker, which contacted MM&M to point out that the study lacked “scientific validity for a number of reasons,” including being approved for one clinical use at the time. Janssen wrote this was a problem because “it is not valid to compare one medicine with a single use to other medicines that have several clinical uses, different durations of therapy and far more patients using treatments.”

Xarelto is approved to reduce stroke risk, to prevent DVT and PE after knee and hip replacements and to treat and prevent DVT and PE. It brought in $864 million in sales last year.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...